Compare Quest Diagnostics Inc (DGX) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Skyworks Solutions Inc — how do they compare? Quest Diagnostics Inc trades at $206.04 (market cap $22.80B), while Skyworks Solutions Inc trades at $55.83 (market cap $8.51B). The key difference: Quest Diagnostics Inc is far larger — about 2.7× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (5.02%). Which is the better fit depends on your goals.
| DGX | SWKS | |
|---|---|---|
Market Cap | $22.80B | $8.51B |
Sector | Health | Technology |
52-Week High | $216.02 | $83.40 |
52-Week Low | $166.42 | $52.50 |
Enterprise Value | $28.82B | $8.28B |
Dividend Yield | 1.67% | 5.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Skyworks Solutions (SWKS) trades at $58.24, down 3.51% amid bearish technical signals, though recent earnings beats and a 60% analyst buy rating suggest underlying strength. The company maintains solid fundamentals with $4.09B revenue and 8.93% net margin, while expanding into AI and EV markets through recent product launches. Cash flow trends show variability, with 2025 net cash flow negative at -$207M after positive flows in prior years.
The stock presents a value opportunity with consensus price target of $72.56 offering 25% upside, supported by dividend yield above 4% and strategic positioning in growing semiconductor segments. Key risks include ongoing legal investigations and customer concentration, but strong analyst support and technical oversold conditions near support at $55 indicate potential for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
